GlassScriptPhysician profile
Trisha K Davis
NPI 1144768946
$3,304.16
in general payments reported to CMS, 2019-2025
29 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $504 · 2022: $741 · 2023: $674 · 2024: $1,086 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.82 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $795.48 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $498.00 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $453.08 | 2021-2024 | Austedo |
| Pfizer INC. | $189.15 | 2024 | |
| Ucb, INC. | $175.28 | 2021-2024 | Briviact, Rystiggo, Fintepla |
| Lilly USA, LLC | $151.39 | 2022-2025 | Reyvow, Emgality, Amyvid |
| Acadia Pharmaceuticals INC | $147.78 | 2021-2024 | Nuplazid |
| Abbott Laboratories | $104.62 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Sk Life Science, INC. | $98.06 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $83.89 | 2021 | |
| Sumitomo Pharma America, INC. | $78.63 | 2023 | Aptiom |
| Emd Serono, INC. | $75.01 | 2022-2024 | Mavenclad |
| Boston Scientific Corporation | $56.28 | 2025 | Rezum Generator |
| Eisai INC. | $45.31 | 2024 | |
| Csl Behring | $41.31 | 2021-2023 | Hizentra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $39.82 | 2023 | Onpattro |
| Allergan, INC. | $32.46 | 2021 | |
| Avanir Pharmaceuticals, INC. | $30.86 | 2022 | |
| Biogen, INC. | $29.63 | 2022-2024 | Spinraza |
| Acorda Therapeutics, INC | $27.29 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $24.50 | 2023 | Nuedexta |
| Genentech USA, INC. | $24.16 | 2024 | Ocrevus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.45 | 2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $16.67 | 2022 | |
| Exact Sciences Corporation | $14.98 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $14.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.54 | 2021 | |
| Impel Pharmaceuticals INC. | $12.94 | 2023 | Trudhesa |
| Aquestive Therapeutics, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.